Literature DB >> 33503570

Treatment and outcomes of nasopharyngeal carcinoma in a unique non-endemic population.

Joel Howlett1, Sarah Hamilton2, Annette Ye3, David Jewett3, Breanna Riou-Green4, Eitan Prisman5, Andrew Thamboo5.   

Abstract

OBJECTIVE: Nasopharyngeal carcinoma (NPC) is common in Southeast Asia. Due to the influx of immigrants from this region, the incidence in British Columbia is increasing. Current literature from non-endemic populations encompasses heterogeneous cohorts. This study examines NPC in a North American population, with a high incidence, to understand the population's characteristics, treatment outcomes and recurrence patterns. METHODS AND MATERIALS: A retrospective analysis of patients treated for primary and recurrent NPC over 15-years. Regression analyses were used to identify predictors of disease recurrence and death. A subgroup analysis of the locoregional recurrence cohort was conducted. Five-year survival outcomes were determined.
RESULTS: 601 patients were included. Asian ethnicity comprised 77% and the majority had non-keratinizing carcinoma (81%). In total, 19.3% of patients experienced recurrence: 58% local, 22% regional and 20% distant. Five-year overall survival was 70%. Smoking, advancing T-stage, poorer performance status and advanced overall stage were all associated with worse overall survival (p < 0.05). Asian ethnicity improved overall survival but not recurrence free survival. Similar features in addition to non-keratinizing histology were associated with increased locoregional recurrence (p < 0.05). Competing risk analysis indicated radiotherapy alone had a higher recurrence relative to chemoradiotherapy (HR 1.91, CI 1.17-3.09, p = 0.01).
CONCLUSIONS: We report the largest study evaluating treatment and outcomes of NPC in a non-endemic population. This unique population falls between described endemic and non-endemic populations. Non-keratinizing pathology and primary radiotherapy did not affect survival; however, both had a propensity for recurrence. Finally, patients experienced more locoregional and less distant recurrence, supporting that this cohort may be amenable to curative salvage therapy.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer; Head and neck; Nasopharyngeal carcinoma; Non-endemic; North America

Year:  2021        PMID: 33503570     DOI: 10.1016/j.oraloncology.2021.105182

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  2 in total

Review 1.  New insights into the tumour immune microenvironment of nasopharyngeal carcinoma.

Authors:  Aisling Forder; Greg L Stewart; Nikita Telkar; Wan L Lam; Cathie Garnis
Journal:  Curr Res Immunol       Date:  2022-09-09

2.  Survival outcomes for patients with nasopharyngeal carcinoma in non-endemic region in the UK treated with intensity modulated based radiotherapy 65 Gy in 30 fractions ± weekly cisplatin chemotherapy.

Authors:  Muhammad Shahid Iqbal; Aung Tin; Abdul Mian; Akram Ali; James O'Hara; Josef Kovarik; Rahul Patil; Eleanor Aynsley; Charles Kelly
Journal:  Rep Pract Oncol Radiother       Date:  2022-07-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.